HOFSETH BIOCARE ASA: årsregnskap 2023 vs 2022
Shrank 100% on revenue, stronger earnings, fresh owner capital
approved 2024-04-18; registry 2024-06-06; journal 2024 428281
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for HOFSETH BIOCARE ASA. Revenue 119.96m NOK → 218.4k NOK (-99.8%). Net result -119.37m NOK → -93.00m NOK. Equity 167.8k NOK → 74.61m NOK.
On the constructive side: operating result improved; net result improved; equity strengthened. Pressures included: revenue fell; cash fell; payroll up without matching revenue.
Also worth watching: book investments changed. All figures are taken from the published annual accounts for HOFSETH BIOCARE ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -112.61m NOK → -86.44m NOK (op. margin -93.9% → -39577.8%). Calculated
-
↑
Net result improved
Net result -119.37m NOK → -93.00m NOK (net margin -99.5% → -42577.1%). Calculated
-
↑
Equity strengthened
Book equity 167.8k NOK → 74.61m NOK (equity ratio 41.7% → 18.8%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 167.8k NOK → 74.61m NOK (+74.44m NOK). Reported fact
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 119.96m NOK to 218.4k NOK (-99.8% YoY). Calculated
-
↓
Cash fell
Bank deposits 31.34m NOK → 22.75m NOK (-27.4% YoY). Calculated
-
↓
Payroll up without matching revenue
Salary cost 47.21m NOK → 51.66m NOK (39% → 23651% of revenue). Calculated
Things to notice
-
·
Book investments changed
Investment / intangible book value 18.09m NOK → 44.70m NOK. Reported fact